NGM120 is a monoclonal antibody antagonist of GFRAL, the receptor for the human hormone GDF15, that holds potential as a treatment for anorexia and cachexia in cancer patients. Under our collaboration agreement, Merck will have a one-time right to exercise an option to license NGM120 following human proof of concept.

Additional information about NGM’s pioneering work on the biology of GFRAL and its ligand, the human hormone GDF15, can be found here.